Oppenheimer Upgrades Intercept Pharmaceuticals (ICPT) to Outperform; Sees Best in Class FXR Agonist for NASH
Tweet Send to a Friend
(Updated - November 19, 2018 5:55 AM EST)(updated to add analyst comments)Oppenheimer analyst Jay Olson upgraded Intercept Pharmaceuticals (NASDAQ: ICPT) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
